Objective:To investigate the clinical efficacy of medium-dose rosuvastatin in patients with acute myocardial infarction after percutaneous coronary intervention(PCI).Methods:The clinical data of 120 patients with acute myocardial infarction treated in Rizhao Hospital of Traditional Chinese Medicine from August 2021 to December 2022 were retrospectively analyzed.All patients were treated with PCI.They were divided into a control group and a study group of 60 patients each according to different dosing doses.The control group received conventional dose(10 mg)of rosuvastatin treatment,while the study group received medium-dose(20 mg)rosuvastatin intensified treatment for 12 weeks.The clinical efficacy,lipid metabolism,matrix metalloproteinase-9,cardiac function,and adverse reactions between two groups.Results:The total effective rate of the observation group was 90.00%,which was higher than 80.00%of the control group,the difference was statistically significant(P＜0.05).After treatment,the levels of total cholesterol,triglycerides,and low-density lipoprotein cholesterol in the study group were lower than those in the control group,and MMP-9,the end diastolic and end systolic diameters of the left ventricle were shorter than those in the control group,and the left ventricular ejection fraction was higher than that in the control group,the differences were statistically significant(P＜0.05).The incidence of adverse reactions in the study group was 5.00%lower than 8.33%in the control group,but there was no statistically significant difference in adverse reactions between the two groups(P＞0.05).Conclusion:Compared with conventional dose rosuvastatin treatment,medium-dose rosuvastatin enhanced treatment has better efficacy in patients with acute myocardial infarction,effectively reducing myocardial cell damage and remodeling,improving cardiac function,and is safe and reliable.
维普
万方数据